

HPAP-172 Donor Summary



HPAP	172	UNOS	
Recovery OPO	IIAM One Legacy	Allocation Via	UPENN <input type="checkbox"/> nPOD <input checked="" type="checkbox"/>
Age (years)	19	DCD	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
Race	Not reported Ethnicity: Hispanic or Latino	DBD	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
Sex	M <input checked="" type="checkbox"/> F <input type="checkbox"/>	Admission to Cross Clamp	<input type="checkbox"/> Hours <input type="checkbox"/> Mins.
ABO (Rh)	B+	Cross Clamp Time	
BMI (Kg/m²)	31.31	Cold Ischemia Time*	<input type="text"/> Hours <input type="text"/> Mins.
Weight (kg)	97.30		
Height (cm)	176.00		
Cause of Death	Head Trauma	Preservation Solution	UW <input type="checkbox"/> HTK <input type="checkbox"/>
Mechanism of Injury	Gunshot Wound	Organs Recovered	Heart <input type="checkbox"/> Kidney <input type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input type="checkbox"/> Liver <input type="checkbox"/> Intestine <input type="checkbox"/>
Cardiac Arrest/Downtime	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity:	<input type="text"/> Hours <input type="text"/> Mins.
CPR / Time	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	Organs Discarded	Heart <input type="checkbox"/> Kidney <input type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input type="checkbox"/> Liver <input type="checkbox"/> Intestine <input type="checkbox"/>
Total Est. Downtime	No Downtime	Blood Culture	No Growth at 5 days.
Date /Time of Admission	02/21/2024 4:20 AM PT	PHS High Risk	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
		Acute Lung Injury	Atelectasis versus early consolidation, right perihilar and infrahilar opacities.

P
P
P
P
P
P

*Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.



HPAP-172 Donor Summary

		Duration	Medications	Compliance
Type of Diabetes	T1D	Unknown	NA	NA
History of cancer	-----	-----	-----	-----
CAD	-----	-----	-----	-----
Hypertension	-----	-----	-----	-----
Hyperlipidemia	-----	-----	-----	-----
Autoimmune disease	-----	-----	-----	-----
Family History	CAD <input type="checkbox"/>	Diabetes <input type="checkbox"/>	Auto immune disease <input type="checkbox"/>	Others:
Surgical History:	PMH includes surgery for a broken left arm 2 years ago.			
Comments:	Social HX: Drunk beer socially 2-4 bottles for 1 year.			

Hemodynamic Profile

Average BP During Hospitalization (mmHg)	127/78	
Average Low BP During Hospitalization		Duration:
Average BP in OR (mmHg)		
Average Low BP in OR (mmHg)		Duration:
Average HR in OR (bpm)		
ABG-pH range	7.29 – 7.54	

P

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	yes	NA	NA
PRBCs	NA	1-5	NA
Platelets	-----	-----	-----
Norepinephrine (Levophed)	-----	1-2 mcg/min started 4 days post admission	
Vasopressin	2.4U/2.4 - 6 ml	Units/hr/ml	430.8
Neo-Synephrine	-----	-----	-----
Epinephrine	-----	-----	-----
Phenylephrine	-----	-----	-----
Dopamine	2.00/ 6.9ml	mcg/kg/min	234.6

HPAP-172 Donor Summary



Blood Products/Meds Transfused Intraoperative

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma			
PRBCs			
Platelets			
Norepinephrine (Levophed)			
Vasopressin			
Neo-Synephrine (phenylephrine)			
Epinephrine			
Dopamine			
Heparin			

P

Initial Autoantibody Screening (nPOD): ELISA

GAD-65	IA-2
GAD+ 2.0	IA2A 1.3

Confirmatory results: Radioimmuno Assay (RIA)

	GAD-65 (unit/ml)	IA-2 (unit/ml)	Insulin AAB (unit/ml)	ZnT8 (unit/ml)
Results	0	0	-0.001	0.001
Cut-off values	20	5	0.01	0.02

*Sample obtained at time of organ recovery.

	C-peptide (ng/ml)	Proinsulin
Results		

P

*Sample obtained at time of organ recovery.

HLA (OPO)*

Class 1	A	2	2	Class II	DR	7	14
	B	35	50		DR51	N-Negative	N-Negative
	C	05	15		DR52	52	N-Negative
	Bw4	Negative			DR53	N-Negative	53
	Bw6	Positive			DQB1	7	8
			DQA1		02	05	
			DPB1		04:01	04:02	
			DPA1		01	01	
Comment:							

HPAP-172 Donor Summary



Confirmatory HLA (UPENN)*

Class 1	A			Class II	DRB1		
	B				DRB3		
	C				DRB4		
					DRB5		
					DQB1		
					DQA1		
					DPB1		
					DPA1		

*HLA typing performed using NGS

Infectious Disease Serology

Test	Result	Hemo/Plasma Dilution Status	
		Qualified	Non-Qualified
EBV IgG (VCA)	Positive	✓	-
EBV IgM (VCA)	Positive	✓	-
CMV IgM	Negative	✓	-
CMV IgG	Positive	✓	-
HBcAb	Negative	✓	-
HBsAg	Negative	✓	-
HCV Ab	Negative	✓	-
HIV I/II	Negative	✓	-
Syphilis	Negative	✓	-
Procleix Ultrio	ND	-	-
Ultrio HBV (HBV NAT)	Negative	✓	-
Ultrio HCV (HCV NAT)	Negative	✓	-
Ultrio HIV (HIV NAT)	Negative	✓	-
Toxoplasma Ab	Negative	✓	-
WNV	Negative	✓	-
SARS-CoV-2	Negative	✓	-

P



HPAP-172 Donor Summary

Laboratory Panel

	Initial	Peak	Terminal
Na (mEq/L) (135-145)	136	154	154
Creatinine (<1.5)	1.16	2.00	1.80
Glucose (mg/dL) (60-150)	233	233	154
HbA1C%	8.3	-----	-----
Total bilirubin (0-1.0)	0.5	1.3	1.3
SGOT (AST) (0-40)	35	54	32
SGPT (ALT) (5-35)	21	94	80
Alkaline phosphatase (45-110)	68	97	92
Serum Amylase (23-851)	21	94	94
Serum Lipase (0-80)	23	59	59
WBC (THO/uL) (4.5-11.0)	13.4	21.4	13.8
Hgb (g/dL) (12-16)	12.1	12.1	10.1
Platelets (THO/uL) (150-350)	275	275	200
INR (<2.0)	1.11	1.79	1.20

Urinalysis

	1 st	2 nd	3 rd	4 th - 17 th
Glucose	Negative	Negative	Negative	Negative

Medications During Hospitalization

Steroids**	Yes, Solumedrol 500.00 mg / 10 00ml		
Diuretics	Yes, Lasix 40.00 mg		
T3 Protocol	-----		
T4 Protocol*	10.0 mcg/hr/25.00mL for the duration of 8:00 hrs started 135:40 hrs post admission		
Insulin**	Yes 5-20 units/hr for the duration of 69 hrs		
Antihypertensive	-----		
Vasodilators	-----		
DDAVP**	-----		
Total parenteral nutrition	-----		
Other	Vancomycin 500-1750 mg , KCL, NS, D5W, Thiamine, FWF, Zosyn3.375g , Vancocin, Diamox	Specify	

*T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015;7 17-27.

** Excluding T4 Protocol